Literature DB >> 18068191

The clinical course of multiple sclerosis patients in Hong Kong.

Kwok-kwong Lau1, Winnie Wing-Yin Wong, Bun Sheng, Ignatius Tak-Sun Yu, Bun-Hey Fung, Ho-Lun Li, Ka-Fai Johnny Ma, Lawrence Ka-Sing Wong, Patrick Chung-Ki Li.   

Abstract

BACKGROUND: Multiple sclerosis (MS) has a low prevalence in Hong Kong.
OBJECTIVE: To reassess MS prevalence in Hong Kong and to examine associated risk factors for relapsing-remitting type MS patients to reach Kurtzke's Extended Disability Status Scale (EDSS) of 6.0, i.e. when walking aid was needed.
DESIGN: Retrospective observational study on MS patients over 11 years.
SETTING: Three tertiary hospitals in Hong Kong.
RESULTS: A hundred and six patients were recruited. Female to male ratio was 3.2:1 and the prevalence was 4.8 per 100,000. 95 were relapsing-remitting (RR) type. The mean disease duration was 12.7 years (range: 1-45 years) and the duration of follow up was 11.0+/-0.8 (mean+/-SE) years. The initial mean EDSS was 1.59 and the latest mean EDSS was 4.26. 38 (40%) RR type MS patients progressed to EDSS 6.0 after a mean duration of 6.0 years. With Cox regression analysis, patients with older age (>35y) of onset (HR 2.57; 95% CI:1.29-5.11), higher EDSS of 2.0 or more upon presentation (HR 2.19; 95%CI: 1.12-4.26) were associated with progression to EDSS of 6.0, while there was a tendency towards slower disease progression for patients initially presenting with optic symptoms (HR 0.52; 95%CI: 0.23-1.16). The number of relapses and use of interferon could not be shown to have significant effect on disease progression.
CONCLUSIONS: The local period prevalence ratio of MS was 4.8 per 100,000. Older age of onset and higher EDSS upon initial presentation were independent predictors for progression to EDSS of 6.0.

Entities:  

Mesh:

Year:  2008        PMID: 18068191     DOI: 10.1016/j.jns.2007.11.006

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Clinical characteristics of optic neuritis in Hong Kong population: 10-year review.

Authors:  Bonnie Nga Kwan Choy; Alex Lap Ki Ng; Jimmy Shiu Ming Lai
Journal:  Int Ophthalmol       Date:  2017-03-13       Impact factor: 2.031

Review 2.  Incidence and prevalence of 121 rare diseases in China: Current status and challenges: 2022 revision.

Authors:  Yanqin Lu; Qingxia Gao; Xiuzhi Ren; Junfeng Li; Dan Yang; Zijian Zhang; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2022-08

3.  Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008.

Authors:  Ching-Piao Tsai; Charles Tzu-Chi Lee
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

4.  Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course.

Authors:  Bahar Kaymakamzade; Ahmet Kasım Kiliç; Aslı Tuncer Kurne; Rana Karabudak
Journal:  Noro Psikiyatr Ars       Date:  2018-07-04       Impact factor: 1.339

5.  Multiple sclerosis in Japan appears to be a milder disease compared to the UK.

Authors:  L Piccolo; G Kumar; I Nakashima; T Misu; Y Kong; B Wakerley; S Ryan; A Cavey; K Fujihara; Jacqueline Palace
Journal:  J Neurol       Date:  2015-01-22       Impact factor: 4.849

Review 6.  The incidence and prevalence, diagnosis, and treatment of multiple sclerosis in China: a narrative review.

Authors:  Dongmei Jia; Yu Zhang; Chunsheng Yang
Journal:  Neurol Sci       Date:  2022-05-18       Impact factor: 3.830

7.  Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis.

Authors:  Alexander Y Lau; W K Ip; Cheryl Au; K K Lau; Winnie Wong; K K Yip; Jonas Yeung; S H Li; Patrick Li; Ryan Lee; Deyond Siu; Jill Abrigo; Adrian Wong; Vincent Mok; Eric Chan
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-10-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.